Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT to Report First Quarter 2018 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 16, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its first quarter on May 1, 2018 .
View HTML
Toggle Summary Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
New Treatment Is Clinically Proven to Reduce Polyps and Symptoms of Nasal Congestion MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 2, 2018-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced U.S.
View HTML
Toggle Summary Intersect ENT Reports Fourth Quarter and Full Year 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 27, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2017 .
View HTML
Toggle Summary Intersect ENT to Report Fourth Quarter and Year 2017 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 8, 2018-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its fourth quarter and year 2017 on February 27,
View HTML
Toggle Summary Intersect ENT to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 24, 2018-- Intersect ENT, Inc. (Nasdaq: XENT ) today announced that management will be presenting at the 7th Annual LEERINK Partners Global Healthcare Conference on Wednesday, February 14, 2018 at 2:30 p.m. ET at the Lotte New York Palace Hotel .
View HTML
Toggle Summary Intersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 22, 2018-- Intersect ENT, Inc. (NASDAQ: XENT) today announced publication of results from a randomized pivotal Phase III study of the company’s SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in
View HTML
Toggle Summary Intersect ENT Reports Preliminary Q4 and Year 2017 Revenue
Full Year Revenue Grew Approximately 22% Year Over Year MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 8, 2018-- Intersect ENT , Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for
View HTML
Toggle Summary Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
Product Offers Targeted Relief for Managing Chronic Condition MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 11, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the
View HTML
Toggle Summary Intersect ENT to Present at the 36th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 7, 2017-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will present an overview of the company's business at the 36 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 p.m. PT at the Westin St.
View HTML
Toggle Summary FDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park Facility
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the U.S. Food and Drug Administration ( FDA ) has performed a Pre-Approval Inspection
View HTML